Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 8/20 | 0.42 |
| ▸ | BECN1 | Q14457 | 6/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179762 | 0.87 | BRD9 (0.44) | BRD4CYP17A1PSMB8BCL2BECN1 | |
| SCHEMBL1179940 | 0.86 | BRD4 (0.43) | BRD4CYP17A1PSMB8BCL2BECN1 | |
| SCHEMBL1180265 | 0.83 | SMO (0.40) | NAMPT | |
| SCHEMBL1179959 | 0.80 | CYP17A1 (0.48) | BRD4CYP17A1PSMB8BRD9NAMPT | |
| SCHEMBL1180515 | 0.79 | CYP17A1 (0.45) | BRD4CYP17A1PSMB8BCL2BECN1 | |
| SCHEMBL12872573 | 0.79 | GPR139 (0.38) | BRD4CYP17A1PSMB8BCL2BECN1 | |
| SCHEMBL1180234 | 0.79 | ADAMTS4 (0.41) | BRD4CYP17A1GPR139 | |
| SCHEMBL1180238 | 0.79 | ADAMTS4 (0.41) | BRD4CYP17A1GPR139 | |
| SCHEMBL12872574 | 0.77 | CYP17A1 (0.40) | BRD4CYP17A1PSMB8BCL2BECN1 | |
| SCHEMBL1180453 | 0.74 | HPGD (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| WO-2009126624-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | BRD4 1858/4885CYP17A1 1538/4885PSMB8 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.